Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olezarsen in FCS patients previously treated with volanesorsen
NCT05185843Phase 3Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Jun 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of olezarsen in familial chylomicronemia syndrome (FCS), sponsored by Ionis Pharmaceuticals. Primary endpoints: Proportion of Participants With Decrease in Platelet Count by >30% or >50%, or With Platelet Count Value <50,000/mm^3 at 209 weeks, Proportion of Participants With Clinical Bleeding Events at 209 weeks and 5 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
olezarsen
03
Conditions
familial chylomicronemia syndrome (FCS)
Beyond the preview
Go deeper on NCT05185843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05185843.